Lung cancer (all types)
Prepared with OnCo (onco.cc/prep/lung-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
13 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14, RET, NTRK, HER2 mutations, PD-L1 expression, Stage by TNM and PET-CT, Circulating tumour DNA for minimal residual disease), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (screening), which of the standard options do you recommend and why?
- 6.How do the results of NLST & NELSON (low-dose CT screening) apply to someone like me?
- 7.For my situation (diagnosis and staging), which of the standard options do you recommend and why?
- 8.For my situation (treatment), which of the standard options do you recommend and why?
- 9.Are there clinical trials I could join, for example of Tarlatamab, Datopotamab deruxtecan?
- 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 12.I read that “Most patients still present with advanced disease”. How does that affect my plan?
- 13.I read that “Resistance to every targeted drug emerges within one to three years”. How does that affect my plan?
Tests and results to bring
Diagnosis and staging: CT, PET-CT, bronchoscopy or CT-guided biopsy, endobronchial ultrasound of nodes, brain MRI; molecular testing on every non-squamous non-small-cell tumour.
Biomarker results to ask for: EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14, RET, NTRK, HER2 mutations (non-small-cell), PD-L1 expression, Stage by TNM and PET-CT, Circulating tumour DNA for minimal residual disease.
Scans and tests linked to this cancer: PET (positron emission tomography), X-ray radiography and fluoroscopy.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Screening: Annual low-dose CT for people aged about 50 to 80 with a heavy smoking history (NLST, NELSON). (NLST & NELSON (low-dose CT screening))
- Treatment: By type and stage on the subtype pages: surgery or stereotactic radiotherapy for early disease, chemoradiation with immunotherapy for locally advanced, targeted or immune therapy for metastatic disease. (Non-small-cell lung cancer, Small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.